Exelixis Inc
NASDAQ: EXEL
$35.63
+$0.80 (+2.3%)
Real Time Data Delayed 15 Min.
EXEL Articles
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
Published:
Last Updated:
As the markets continue to stumble through May, and the volatility appears to be creeping up some, the end of the first-quarter earnings parade has opened the door for insiders to buy shares.
Published:
Last Updated:
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates for generic...
Published:
Last Updated:
Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.
Published:
Last Updated:
Exelixis Inc. (NASDAQ: EXEL) was up slightly in Tuesday’s trading session following positive results from a late stage trial. The company announced the presentation of positive data from subgroup...
Published:
Last Updated:
On the close Tuesday, the PowerShares Dynamic exchange traded funds (ETFs) are set for a rebalance. These four stocks that are expected to have huge buying on the close Tuesday.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
Published:
It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical trial and get more bang for its buck.
Published:
The most recent clinical trial results may have put Exelixis back on the map as a potential buyout.
Published:
24/7 Wall St. has taken a look at some of the major ASCO winners over the past week and how they have performed since before the ASCO news.
Published:
24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background information has also been added on each, as well as how shares have been moving and the consensus price...
Published:
Exelixis is seeing an outright implosion in its stock after news of its Phase 3 metastatic prostate cancer not meeting its primary endpoint.
Published:
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Tuesday, September 2, 2014.
Published:
ThinkstockCancer treatment developer Exelixis Inc. (NASDAQ: EXEL) is trading very heavy volume today and getting a sharp price boost following a positive result in a phase 3 pivotal trial of a...
Published:
Last Updated:
Exelixis may have a while longer before it gets to be a serious revenue stage company. Its stock was crushed on Wednesday, and the company has lost its $1 billion market cap.
Published: